to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback